We present the first randomized, double-blind, placebo-controlled

We present the first randomized, double-blind, placebo-controlled clinical trial of MA versus placebo in children with cancer and weight loss.

MethodsSubjects smaller than 18 years of age with weight loss (minimum 5% from highest previous weight; or %ideal body weight smaller than 90%) due to cancer and/or cancer therapy were randomized to either MA (7.5mg/kg/day) or placebo for a planned study duration of 90 days. Primary outcome was the difference between groups in mean percent weight change from beginning PRIMA-1MET concentration to end of the study period. Secondary outcomes included effects on anthropometrics, body composition, need for tube feeding or parenteral nutrition, and toxicities. ResultsTwenty-six patients were randomly assigned (13 MA, 13 placebo). The MA group experienced a mean weight gain of +19.7% compared to a mean weight loss of -1.2% in the placebo group, for a difference of +20.9% (95%CI: +11.3% to +30.5%, P=0.003) in favor of MA over placebo. MA subjects experienced significant increases in weight for age z-scores, body mass index z-scores, and mid upper arm circumference compared to placebo. DXA scanning suggested disproportionate increases in fat accrual. Adrenal suppression was

the main toxicity of MA. ConclusionIn children with high-risk malignancies, MA resulted in significant increases in mean percent weight change compared to placebo. Further studies of MA should be pursued to better delineate the effect on nutritional status. Pediatr Blood Cancer 2014;61:672-679. (c) 2013 Wiley Periodicals, Inc.”
“Individuals with Lennox-Gastaut syndrome (LGS) often do not respond to or become KPT-8602 clinical trial resistant to pharmacologic treatments. Ketogenic diets (KDs) and vagus nerve stimulation (VNS) are nonpharmacologic treatment options for these intractable patients. The classic KD, a high-fat, low-carbohydrate diet with 90% of calories derived from

fat, has been used in the treatment of seizures for bigger than 90years. About half of patients with LGS respond to the KD with a bigger than 50% reduction in seizures and some patients may achieve a bigger than 90% reduction. Ro-3306 solubility dmso Vagus nerve stimulation therapy involves a surgically implanted generator that delivers intermittent electrical stimuli to the brain via an electrode wrapped around the left vagus nerve. It is utilized as adjunctive therapy for patients with drug-resistant epilepsy (including patients with LGS) who are not suitable candidates for resective surgery. Similar to the KD, about half of LGS patients respond to VNS therapy, with a bigger than 50% reduction in seizures, and the response may improve over time. Both the KD and VNS are options for patients with LGS.”
“Hypotonicity triggered in human hepatoma cells (Huh-7) the release of ATP and cell swelling, followed by volume regulatory decrease (RVD). We analyzed how the interaction between those processes modulates cell volume. Cells exposed to hypotonic medium swelled 1.5 times their basal volume.

Comments are closed.